Bioceltix

Bioceltix Gross Profit

The Gross Profit of Bioceltix (BCX.WA) as of Nov 5, 2026 is -680,062.00 PLN. In the previous year, Gross Profit was -574,435.00 PLN — a change of 18.39% (lower).

Gross Profit

-680,062.00PLN

YoY

18.39%

Last updated:

Gross Profit of Bioceltix is 2025 -680,062.00 PLN. Gross Profit of Bioceltix was 2024 -574,435.00 PLN. It decreases by 18.39% lower compared to the previous year.

The Bioceltix Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
-1.81 M PLN
Jan 1, 2019
-3.48 M PLN
Jan 1, 2020
-3.87 M PLN
Jan 1, 2021
-376,978.00 PLN
Jan 1, 2022
-445,385.00 PLN
Jan 1, 2023
-1.04 M PLN
Jan 1, 2024
-574,435.00 PLN
Jan 1, 2025
-680,062.00 PLN
The Bioceltix Gross Profit history
YEARGross ProfitYoY
-680,062.00PLN+18.39%
-574,435.00PLN-44.66%
-1.04 MPLN+133.07%
-445,385.00PLN+18.15%
-376,978.00PLN-90.25%
-3.87 MPLN+11.11%
-3.48 MPLN+92.73%
-1.81 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioceltix Revenue

Bioceltix Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
0.00 PLN
-6.21 M PLN
-4.40 M PLN
Jan 1, 2022
0.00 PLN
-9.67 M PLN
-8.92 M PLN
Jan 1, 2023
0.00 PLN
-15.82 M PLN
-13.69 M PLN
Jan 1, 2024
0.00 PLN
-18.83 M PLN
-14.90 M PLN
Jan 1, 2025
0.00 PLN
-17.32 M PLN
-15.16 M PLN
Jan 1, 2026 (e)
21.50 M PLN
-18.83 M PLN
-21.01 M PLN
Jan 1, 2027 (e)
29.50 M PLN
9.66 M PLN
8.30 M PLN
Jan 1, 2028 (e)
49.35 M PLN
16.30 M PLN
14.10 M PLN

Bioceltix Margins

Bioceltix stock margins

The Bioceltix margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bioceltix. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bioceltix.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-35,806.30 %
- %
- %
Jan 1, 2022
-35,806.30 %
- %
- %
Jan 1, 2023
-35,806.30 %
- %
- %
Jan 1, 2024
-35,806.30 %
- %
- %
Jan 1, 2025
-35,806.30 %
- %
- %
Jan 1, 2026 (e)
-35,806.30 %
-87.58 %
-97.74 %
Jan 1, 2027 (e)
-35,806.30 %
32.74 %
28.12 %
Jan 1, 2028 (e)
-35,806.30 %
33.03 %
28.57 %

Bioceltix Stock analysis

What does Bioceltix do? Bioceltix SA focuses on research and development within the field of veterinary medicine, specifically targeting the treatment of companion animals. The company develops candidates for veterinary medicinal products by utilizing the immunomodulatory properties of mesenchymal stem cells as the active substance. This scientific approach allows the firm to conduct research and development works that facilitate clinical trials and the full registration of these medicinal products with the European Medicines Agency, adhering to standards similar to those for human medicines. Bioceltix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioceltix stock

Gross Profit of Bioceltix is -680,062.00 PLN in 2025.

Gross Profit of Bioceltix changed from -574,435.00 PLN to -680,062.00 PLN, representing a 18.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Bioceltix since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Bioceltix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Bioceltix

All Key Metrics — Bioceltix